Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 134Active not recruiting 57Terminated 38Recruiting 32Withdrawn 18Unknown 17Not yet recruiting 2Approved for marketing 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Waldenstrom Macroglobulinemia 2Multiple Myeloma 1

Interventions

Cisplatin 122Carboplatin 121Drug Therapy 118Bevacizumab 105Capecitabine 99Oxaliplatin 97Radiotherapy 95Paclitaxel 88Gemcitabine 88tislelizumab 87Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 65Fluorouracil 62sintilimab 59Injections 57Surgical Procedures, Operative 56Docetaxel 54anlotinib 51130-nm albumin-bound paclitaxel 48Immune Checkpoint Inhibitors 47fludarabine 46Standard of Care 45Pemetrexed 43Blood Specimen Collection 43Biopsy 43venetoclax 41lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × ibrutinib × Clear all
NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting
400 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Not yet recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡